Previous 10 | Next 10 |
Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have seen major advances recently, one of the leading being with medical devices that use el...
PLANO, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller’s retirement from the Board, ...
The following slide deck was published by Nuvectra Corporation in conjunction with this Read more ...
Nuvectra Corporation (NVTR) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Tram Bui - The Ruth Group Fred Parks - Chief Executive Officer Walter Berger - Chief Operating Officer and Chief Financial Officer Conference Call Participants Mat...
Nuvectra Corporation (NASDAQ: NVTR ): Q4 GAAP EPS of -$0.65 beats by $0.20 . More news on: Nuvectra Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
PLANO, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2018. Recent Highlights Record consolidated revenues of $14.5 mil...
PLANO, Texas, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present a...
POINT ROBERTS, Wash. and DELTA, British Columbia, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Investorideas.com , a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many o...
- The Human Genome Project changed the scientific landscape completely, spurring major public and private investment into understanding human DNA. We're still benefitting from this effort as the science bears fruit in the form of new healthcare technology and even public market winners: ILM...
PLANO, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, February 28, 2019 after market...
News, Short Squeeze, Breakout and More Instantly...
Court-Supervised Process Has No Impact on Safety or Functionality of Algovita Device; Company Continuing to Support Physicians PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR) (“Nuvectra” or the “Company”), a neurostimulati...
PLANO, Texas, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced it has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration (FDA) in support of the Comp...
PLANO, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Jennifer Kosharek as Chief Financial Officer, effective September 16, 2019. Ms. Kosharek will assume the role of Chief Financia...